-
Epizyme Announces Closing of Concurrent Public Offerings and Full Exercise of Underwriter’s Option to Purchase Additional Shares
-
Epizyme Announces Pricing of Concurrent Public Offerings of Common Stock and Series A Preferred Stock
-
Epizyme (EPZM) to Offer Common Stock and Preferred Stock
-
Epizyme Announces Proposed Concurrent Public Offerings of Common Stock and Series A Preferred Stock
-
Epizyme (EPZM) PT Lowered to $28 at Citi
-
Epizyme (EPZM) PT Lowered to $29 at Citi
-
Epizyme (EPZM) Removed from Citi Catalyst Watch
-
Epizyme to Participate in Upcoming Investor Conferences
-
Pre-Open Movers 04/24: (EVLV) (SANM) (WFT) Higher; (EPZM) (WAT) (MMM) Lower (more...)
-
Epizyme (EPZM) PT Raised to $30 at Citi Citing 'Multiple Avenues for Upside'
-
Epizyme to Participate in Upcoming Investor Conferences
-
Epizyme (EPZM) PT Raised to $22 at Citi
-
Epizyme to Present at Upcoming Investor Conferences
-
Notable Analyst Rating Changes 4/5: (CHMT) (SXL) (ICPT) Upgraded; (LPLA) (LYB) (HRL) Downgraded
-
Citi Starts Epizyme (EPZM) at Buy
-
Epizyme Announces Closing of Public Offering of Common Stock
-
Epizyme (EPZM) Prices 13.33M Common Offering at $9/Share
-
Epizyme Announces Pricing of Public Offering of Common Stock
-
Epizyme (EPZM) Annoucnes $120M Common Stock Offering
-
Epizyme Announces Proposed Public Offering of Common Stock
-
Epizyme, Inc. to Present at Upcoming Events in September
-
Three Small Cap Biotech Stocks Added to Citi's Most Preferred List (ATRA) (NVAX) (PBYI)
-
Epizyme (EPZM) Announces 4.2M Common Stock Offering
-
Notable Analyst Rating Changes 06/25: (MRVL) (LVS) (LRCX) Upgraded; (NFLX) (PAAS) (DMD) Downgraded
-
Citi Starts Epizyme (EPZM) at Buy
-
Epizyme (EPZM) Plans to Sell 4.29M Common in IPO
-
Epizyme (EPZM) Files $69M IPO